Rhoen-Klinikum AG
Rhoen-Klinikum AG Fundamental Analysis
Rhoen-Klinikum AG (RHK.SW) shows weak financial fundamentals with a PE ratio of 65.48, profit margin of 2.24%, and ROE of 2.17%. The company generates $0.5B in annual revenue with weak year-over-year growth of -8.02%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 24.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze RHK.SW's fundamental strength across five key dimensions:
Efficiency Score
WeakRHK.SW struggles to generate sufficient returns from assets.
Valuation Score
ModerateRHK.SW shows balanced valuation metrics.
Growth Score
ModerateRHK.SW shows steady but slowing expansion.
Financial Health Score
ExcellentRHK.SW maintains a strong and stable balance sheet.
Profitability Score
WeakRHK.SW struggles to sustain strong margins.
Key Financial Metrics
Is RHK.SW Expensive or Cheap?
P/E Ratio
RHK.SW trades at 65.48 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, RHK.SW's PEG of -3.01 indicates potential undervaluation.
Price to Book
The market values Rhoen-Klinikum AG at 1.43 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 9.98 times EBITDA. This is generally considered low.
How Well Does RHK.SW Make Money?
Net Profit Margin
For every $100 in sales, Rhoen-Klinikum AG keeps $2.24 as profit after all expenses.
Operating Margin
Core operations generate 2.87 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.17 in profit for every $100 of shareholder equity.
ROA
Rhoen-Klinikum AG generates $1.52 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Rhoen-Klinikum AG generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Rhoen-Klinikum AG generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
RHK.SW converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
65.48
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-3.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.43
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.67
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.11
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.28
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How RHK.SW Stacks Against Its Sector Peers
| Metric | RHK.SW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 65.48 | 29.88 | Worse (Expensive) |
| ROE | 2.17% | 682.00% | Weak |
| Net Margin | 2.24% | -46037.00% (disorted) | Weak |
| Debt/Equity | 0.11 | 0.42 | Strong (Low Leverage) |
| Current Ratio | 2.28 | 4.49 | Strong Liquidity |
| ROA | 1.52% | -16420.00% (disorted) | Weak |
RHK.SW outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Rhoen-Klinikum AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
22.37%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
0.17%
Industry Style: Defensive, Growth, Innovation
GrowingFCF CAGR
169.77%
Industry Style: Defensive, Growth, Innovation
High Growth